May 5, 2025
| Today’s news and insights for biopharma leaders
While updated study results confirmed the drug lowers a target protein, the therapy's effect on clinical outcomes was less clear-cut.
|
The firm, a prolific backer of drug startups, will use the cash to back companies working on therapeutics, medical devices and healthcare services.
|
The cuts to three advanced drug programs were “inevitable” given the company’s “unsustainable cash burn,” one analyst wrote in a note to investors.
|
Discover how to overcome complexity, cut delays and maximize ROI in clinical trials.
|
Tracker
A budget outline released by the administration shows it aims to lower HHS spending by about 26% next year, with deep cuts at the NIH and CDC.
|
Sales of the company’s copycat to J&J’s blockbuster reached $150 million in the first quarter, adding to a surge in revenue for Amgen's biosimilar business.
|
|
Stronger connections lead to better outcomes. In this infographic, learn how to use key moments in the product lifecycle, from drug discovery to commercialization, to help transform patient care.
|
|
From Our Library
Trendline
Supported by Phil Inc
|
Trendline
Supported by EVERSANA
|
Trendline
Supported by Catalent
|
Infographic
Custom content for WCG
|
| 
